Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2023 Oct;56(3):495-498.
doi: 10.1007/s11239-023-02865-z. Epub 2023 Jul 15.

Enoxaparin for COVID-19: a systematic review and meta-analysis of randomized controlled trials

Muhammad Ehsan #  1 , Uzair Jafar #  2 , Momina Butt  2 , Aiman Naveed  2 , Mohammad Umer  2 , Muhammad Ayyan  2 , Biah Mustafa  2 , Rehmat Ullah Awan  3
Affiliations
Meta-Analysis

Enoxaparin for COVID-19: a systematic review and meta-analysis of randomized controlled trials

Muhammad Ehsan et al. J Thromb Thrombolysis. 2023 Oct.
No abstract available

PubMed Disclaimer

References

    1. World Health Organization (2022) Coronavirus disease (COVID-19) pandemic. World Health Organization, Geneva
    1. Hadid T, Kafri Z, Al-Katib A (2021) Coagulation and anticoagulation in COVID-19. Blood Rev 47:100761. https://doi.org/10.1016/j.blre.2020.100761 - DOI - PubMed
    1. Barco S, Voci D, Held U et al (2022) Enoxaparin for primary thromboprophylaxis in symptomatic outpatients with COVID-19 (OVID): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet Haematol 9:e585–e593. https://doi.org/10.1016/S2352-3026(22)00175-2 - DOI - PubMed - PMC
    1. Voci D, Götschi A, Held U et al (2023) Enoxaparin for outpatients with COVID-19: 90-day results from the randomised, open-label, parallel-group, multinational, phase III OVID trial. Thromb Res 221:157–163. https://doi.org/10.1016/j.thromres.2022.10.021 - DOI - PubMed
    1. Cools F, Virdone S, Sawhney J et al (2022) Thromboprophylactic low-molecular-weight heparin versus standard of care in unvaccinated, at-risk outpatients with COVID-19 (ETHIC): an open-label, multicentre, randomised, controlled, phase 3b trial. Lancet Haematol 9:e594–e604. https://doi.org/10.1016/S2352-3026(22)00173-9 - DOI - PubMed - PMC

LinkOut - more resources